Zobrazeno 1 - 10
of 139
pro vyhledávání: '"Robert Croop"'
Publikováno v:
Pain and Therapy, Vol 13, Iss 5, Pp 1203-1218 (2024)
Abstract Introduction Cardiovascular (CV) risk factors can limit treatment options for migraine. Rimegepant is an orally administered small-molecule calcitonin gene-related peptide receptor antagonist that does not induce vasoconstriction. The aim of
Externí odkaz:
https://doaj.org/article/eab56d52d73d464e914295854e7b80f1
Autor:
Shengyuan Yu, Aihong Guo, Zhen Wang, Jianguang Liu, Ge Tan, Qian Yang, Mingjie Zhang, Hasiyeti Yibulaiyin, Huisheng Chen, Yongbo Zhang, Robert Croop, Yanhui Sun, Yu Liu, Qian Zhao, Zhihong Lu
Publikováno v:
The Journal of Headache and Pain, Vol 25, Iss 1, Pp 1-11 (2024)
Abstract Background Rimegepant orally disintegrating tablet (ODT), an oral small-molecule calcitonin gene-related peptide receptor antagonist, is indicated for acute and preventive treatment of migraine in the United States and other countries. Previ
Externí odkaz:
https://doaj.org/article/d31973ea829d4c36829aa7c5d2e08a32
Autor:
Rajinder Bhardwaj, Mary K. Donohue, Jennifer Madonia, Beth Morris, Thomas C. Marbury, Kyle T. Matschke, Robert Croop, Richard Bertz, Jing Liu
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 7, Pp n/a-n/a (2024)
Abstract Zavegepant, a high‐affinity, selective, small‐molecule calcitonin gene‐related peptide (CGRP) receptor antagonist, is approved in the United States for acute treatment of migraine in adults. The effects of moderate hepatic impairment (
Externí odkaz:
https://doaj.org/article/7633456a305843bd910ec34af3475719
Autor:
Gilbert L’Italien, Evan Popoff, Karissa Johnston, Donnie McGrath, Charles M Conway, Lauren Powell, Linda Harris, Nicole Kowalczyk, Robert Croop, Vladimir Coric
Publikováno v:
Cephalalgia Reports, Vol 5 (2022)
Background: Rimegepant, a small molecule oral calcitonin gene-related peptide (CGRP) receptor antagonist, is approved for the acute and preventive treatment of migraine. We hypothesized that intermittent CGRP receptor blockade with rimegepant 75 mg a
Externí odkaz:
https://doaj.org/article/d3138efbe223411389222aae5a2240a0
Autor:
Shengyuan Yu, Byung-Kun Kim, Aihong Guo, Man-Ho Kim, Mingjie Zhang, Zhen Wang, Jianguang Liu, Heui-Soo Moon, Ge Tan, Qian Yang, Donnie McGrath, Michael Hanna, David A Stock, Yanfei Gao, Robert Croop, Zhihong Lu
Publikováno v:
The Lancet Neurology. 22:476-484
Autor:
Richard B Lipton, Robert Croop, David A Stock, Jennifer Madonia, Micaela Forshaw, Meghan Lovegren, Linda Mosher, Vladimir Coric, Peter J Goadsby
Publikováno v:
The Lancet Neurology. 22:209-217
Autor:
Robert Croop, Andrea Ivans, Matt S Anderson, Joseph Stringfellow, Richard Bertz, Michael Hanna, Francine Healy, David A Stock, Vladimir Coric, Richard B Lipton
Publikováno v:
Cephalalgia Reports, Vol 4 (2021)
Objective: This randomized, partially-blinded, placebo-controlled study evaluated hemodynamic effects, pharmacokinetic interactions, and safety of concomitant administration of oral rimegepant and subcutaneous sumatriptan. Methods: Healthy non-smoker
Externí odkaz:
https://doaj.org/article/fe282c055cbf43db97ccc7a665dc4fbe
Autor:
Lauren C. Powell, Gilbert L’Italien, Evan Popoff, Karissa Johnston, Fiona O’Sullivan, Linda Harris, Robert Croop, Vladimir Coric, Richard B. Lipton
Publikováno v:
Advances in Therapy. 40:585-600
Autor:
Robert, Croop, Jennifer, Madonia, David A, Stock, Alexandra, Thiry, Micaela, Forshaw, Abigail, Murphy, Vladimir, Coric, Richard B, Lipton
Publikováno v:
Headache: The Journal of Head and Face Pain. 62:1153-1163
Evaluate the efficacy, safety, and tolerability of zavegepant nasal spray in the acute treatment of migraine.Calcitonin gene-related peptide-targeting agents are a novel class of therapeutics for migraine, but none are currently available as a nonora
Autor:
Karissa M, Johnston, Lauren, Powell, Evan, Popoff, Linda, Harris, Robert, Croop, Vladimir, Coric, Gilbert, L'Italien
Publikováno v:
The Clinical Journal of Pain. 38:680-685
To develop and compare benefit-risk profiles for rimegepant, ubrogepant, and lasmiditan based on a network meta-analysis (NMA) of published clinical trials.A fixed-effects Bayesian NMA of randomized controlled trials of lasmiditan, rimegepant, and ub